Showing 2,801 - 2,820 results of 18,314 for search 'significantly ((((largest decrease) OR (mean decrease))) OR (((nn decrease) OR (a decrease))))', query time: 0.68s Refine Results
  1. 2801

    Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
  2. 2802

    Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
  3. 2803

    Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
  4. 2804

    Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
  5. 2805

    Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
  6. 2806

    Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
  7. 2807

    Image 4_The immunomodulatory and antitumor properties of the bacterial metalloprotease Oligopeptidase A are mediated by TLR4/MyD88/TRIF and MAPK signaling pathways.tiff by Priscila Silva (556743)

    Published 2025
    “…</p>Results<p>Heat-inactivated OpdA significantly reduced metastasis, dependent on tumor-specific CD4+ and CD8+ T cells and IFN-γ, both locally and systemically, with decreased IL-10 levels suggesting a proinflammatory environment. …”
  8. 2808

    Image 2_The immunomodulatory and antitumor properties of the bacterial metalloprotease Oligopeptidase A are mediated by TLR4/MyD88/TRIF and MAPK signaling pathways.tiff by Priscila Silva (556743)

    Published 2025
    “…</p>Results<p>Heat-inactivated OpdA significantly reduced metastasis, dependent on tumor-specific CD4+ and CD8+ T cells and IFN-γ, both locally and systemically, with decreased IL-10 levels suggesting a proinflammatory environment. …”
  9. 2809

    Image 1_The immunomodulatory and antitumor properties of the bacterial metalloprotease Oligopeptidase A are mediated by TLR4/MyD88/TRIF and MAPK signaling pathways.tif by Priscila Silva (556743)

    Published 2025
    “…</p>Results<p>Heat-inactivated OpdA significantly reduced metastasis, dependent on tumor-specific CD4+ and CD8+ T cells and IFN-γ, both locally and systemically, with decreased IL-10 levels suggesting a proinflammatory environment. …”
  10. 2810

    Image 3_The immunomodulatory and antitumor properties of the bacterial metalloprotease Oligopeptidase A are mediated by TLR4/MyD88/TRIF and MAPK signaling pathways.tiff by Priscila Silva (556743)

    Published 2025
    “…</p>Results<p>Heat-inactivated OpdA significantly reduced metastasis, dependent on tumor-specific CD4+ and CD8+ T cells and IFN-γ, both locally and systemically, with decreased IL-10 levels suggesting a proinflammatory environment. …”
  11. 2811

    The epidemiology and gene mutation characteristics of pyrazinamide-resistant <i>Mycobacterium tuberculosis</i> clinical isolates in Southern China by Nan Wang (21935)

    Published 2025
    “…This difference in the <i>rpsA</i> mutation rate was statistically significant (<i>P = 0.001</i>, chi-square test). …”
  12. 2812
  13. 2813

    Participant characteristics. by Ronald Kusolo (13200268)

    Published 2025
    “…The risk factor prevalences that decreased significantly were: inadequate physical activity from 5.0% in 2014 to 3.6% in 2023 (p=0.003), and current smoke tobacco use from 9.6% in 2014, to 8.3% in 2023 (p= 0.046). …”
  14. 2814
  15. 2815
  16. 2816

    Uganda 2023 NCD risk factor STEPS survey data. by Ronald Kusolo (13200268)

    Published 2025
    “…The risk factor prevalences that decreased significantly were: inadequate physical activity from 5.0% in 2014 to 3.6% in 2023 (p=0.003), and current smoke tobacco use from 9.6% in 2014, to 8.3% in 2023 (p= 0.046). …”
  17. 2817

    Uganda 2014 NCD risk factor STEPS survey data. by Ronald Kusolo (13200268)

    Published 2025
    “…The risk factor prevalences that decreased significantly were: inadequate physical activity from 5.0% in 2014 to 3.6% in 2023 (p=0.003), and current smoke tobacco use from 9.6% in 2014, to 8.3% in 2023 (p= 0.046). …”
  18. 2818

    Assessment of calcium events, pERK levels, NMDA receptor expression and extracellular zinc levels in <i>slc13a5</i> mutants. by Deepika Dogra (21072023)

    Published 2025
    “…<b>(M, M’, N, N’,</b> Q) Quantification of the fluorescence intensity (CTCF) ratios of Palm-ZP1:CellMask Orange in the plasma membrane. <i>5a</i><sup><i>−/−</i></sup><i>;5b</i><sup><i>−/−</i></sup> larvae show a significant decrease in Palm-ZP1:CellMask Orange CTCF ratio in the plasma membrane compared to WTs. …”
  19. 2819
  20. 2820